Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer (NSCLC): results of the phase 3 CheckMate 078 study

被引：2
|
作者：
Wu, Yi-Long [1 ]
Lu, Shun [2 ]
Cheng, Ying [3 ]
Zhou, Caicun [4 ]
Wang, Jie [5 ]
Mok, Tony [6 ]
Zhang, Li [7 ]
Tu, Haiyan [1 ]
Wu, Lin [8 ]
Feng, Jifeng [9 ]
Zhang, Yiping [10 ]
Luft, Alexander Valeriercich [11 ]
Zhou, Jianying [12 ]
Ma, Zhiyong [13 ]
Lu, You [14 ]
Hu, Chengping [15 ]
Shi, Yuankai [16 ,17 ]
Baudelet, Christine [18 ]
Li, Zoe [18 ]
Chang, Jianhua [19 ]
机构：
[1] Guandong Gen Hosp, Guangzhou, Guangdong, Peoples R China
[2] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Shanghai Lung Canc Ctr, Shanghai, Peoples R China
[3] Jilin Canc Hosp, Changchun, Jilin, Peoples R China
[4] Shanghai Pulm Hosp, Shanghai, Peoples R China
[5] Chinese Acad Med Sci, Beijing, Peoples R China
[6] Chinese Univ Hong Kong, Shatin, Hong Kong, Peoples R China
[7] Sun Yat Sen Univ, Guangzhou, Guangdong, Peoples R China
[8] Hunan Canc Hosp, Changsha, Hunan, Peoples R China
[9] Jiangsu Canc Hosp, Beijing, Peoples R China
[10] Zhejiang Canc Hosp, Hangzhou, Zhejiang, Peoples R China
[11] Leningrad Reg Clin Hosp, St Petersburg, Russia
[12] Zhejiang Univ, Affiliated Hosp 1, Coll Med, Hangzhou, Zhejiang, Peoples R China
[13] Henan Canc Hosp, Zhengzhou, Henan, Peoples R China
[14] West China Hosp, Chengdu, Sichuan, Peoples R China
[15] Cent S Univ, Xiangya Hosp, Changsha, Hunan, Peoples R China
[16] Chinese Acad Med Sci, Natl Canc Ctr, Canc Hosp, Beijing, Peoples R China
[17] Peking Union Med Coll, Beijing, Peoples R China
[18] Bristol Myers Squibb, Princeton, NJ USA
[19] Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China
来源：
CANCER RESEARCH | 2018年 / 78卷 / 13期
关键词：
D O I：
10.1158/1538-7445.AM2018-CT114
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT114
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical Trial
    Wu, Yi-Long
    Lu, Shun
    Cheng, Ying
    Zhou, Caicun
    Wang, Jie
    Mok, Tony
    Zhang, Li
    Tu, Hai-Yan
    Wu, Lin
    Feng, Jifeng
    Zhang, Yiping
    Luft, Alexander Valerievich
    Zhou, Jianying
    Ma, Zhiyong
    Lu, You
    Hu, Chengping
    Shi, Yuankai
    Baudelet, Christine
    Cai, Junliang
    Chang, Jianhua
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (05) : 867 - 875
  • [2] Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer: 2-year follow-up from a randomized, open-label, phase 3 study (CheckMate 078)
    Lu, Shun
    Wang, Jie
    Cheng, Ying
    Mok, Tony
    Chang, Jianhua
    Zhang, Li
    Feng, Jifeng
    Tu, Hai-Yan
    Wu, Lin
    Zhang, Yiping
    Luft, Alexander
    Zhou, Jian-Ying
    Ma, Zhiyong
    Lu, You
    Hu, Chengping
    Shi, Yuankai
    Ying, Kejing
    Zhong, Hua
    Poddubskaya, Elena
    Soo, Ross A.
    Chia, Yee Hong
    Li, Ang
    Li, Amy
    Wu, Yi-Long
    LUNG CANCER, 2021, 152 : 7 - 14
  • [3] Three-year follow-up and patient-reported outcomes from CheckMate 078: Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer
    Chang, Jianhua
    Wu, Yi-Long
    Lu, Shun
    Wang, Jie
    Mok, Tony
    Zhang, Li
    Feng, Jifeng
    Wu, Lin
    Tu, Hai-Yan
    Zhang, Yiping
    Luft, Alexander
    Zhou, Jian-ying
    Ma, Zhiyong
    Lu, You
    Hu, Chengping
    Shi, Yuankai
    Poddubskaya, Elena
    Soo, Ross A.
    Chia, Yee Hong
    Penrod, John R.
    Taylor, Fiona
    Lawrance, Rachael
    Blum, Steven, I
    Sun, Xiaowu
    Juarez-Garcia, Ariadna
    Moreno-Koehler, Alejandro
    Li, Ang
    Li, Amy
    Cheng, Ying
    LUNG CANCER, 2022, 165 : 71 - 81
  • [4] CheckMate 078: Patient-Reported Outcomes (PROs) With Nivolumab vs Docetaxel in Advanced Non-Small Cell Lung Cancer (NSCLC)
    Wu, Y.
    Chang, J.
    Zhang, L.
    Tu, H.
    Wu, L.
    Feng, J.
    Lu, S.
    Zhou, C.
    Wang, J.
    Mok, T.
    Taylor, F.
    Mossman, B.
    Penrod, J.
    Lawrance, R.
    Blum, S.
    Wang, P. F.
    Cheng, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (12) : S1047 - S1048
  • [5] HEALTH CARE RESOURCE UTILIZATION (HCRU) OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) TREATED WITH NIVOLUMAB VERSUS DOCETAXEL: RESULTS FROM THE CHECKMATE 078 (CM078) TRIAL
    Lawrance, R.
    DeRosa, M.
    Taylor, F.
    Penrod, J. R.
    Shaw, J. W.
    Wang, P. F.
    VALUE IN HEALTH, 2019, 22 : S79 - S79
  • [6] Feasibility Study of Nivolumab and Docetaxel in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer
    Shimokawa, T.
    Nakamura, Y.
    Iwasawa, S.
    Miyazaki, K.
    Yamanaka, T.
    Takiguchi, Y.
    Okamoto, H.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2431 - S2431
  • [7] Feasibility study of nivolumab and docetaxel in previously treated patients with advanced non-small cell lung cancer
    Miyazaki, Kazuhito
    Iwasawa, Shunichiro
    Nakamura, Yukiko
    Shimokawa, Tsuneo
    Yamanaka, Takeharu
    Takiguchi, Yuichi
    Okamoto, Hiroaki
    ANNALS OF ONCOLOGY, 2017, 28
  • [8] Nivolumab Versus Docetaxel in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer and Liver Metastases
    Crino, L.
    Horn, L.
    Felip, E.
    Frontera, O. Aren
    Burgio, M.
    Waterhouse, D.
    Blumenschein, G.
    Barlesi, F.
    Garassino, M.
    Holgado, E.
    Antonia, S.
    Spigel, D.
    Gainor, J.
    Gettinger, S.
    Geese, W.
    Li, A.
    Healey, D.
    Ready, N.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2302 - S2302
  • [9] SAPPHIRE: Phase III study of sitravatinib plus nivolumab versus docetaxel in patients with previously treated advanced non-squamous non-small cell lung cancer (NSCLC)
    Borghaei, H.
    Johnson, M. L.
    Garon, E. B.
    He, K.
    Planchard, D.
    Reck, M.
    Popat, S.
    Herbst, R. S.
    Leal, T. A.
    Dumoulin, D.
    De Marinis, F.
    Reynolds, C. H.
    Theelen, W. S. M. E.
    Percent, I.
    Calderon, V. Gutierrez
    Flandin, A. C. Madroszyk
    Shazer, R. L.
    Yan, X.
    Harrigan, R.
    Peters, S.
    ANNALS OF ONCOLOGY, 2023, 34 : S1308 - S1308
  • [10] Three-Year Follow-Up From checkMate 017/057: Nivolumab Versus Docetaxel in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC)
    Felip, Enriqueta
    Gettinger, Scott
    Burgio, Marco Angelo
    Antonia, Scott J.
    Holgado, Esther
    Spigel, David
    Arrieta, Oscar
    Domine, Manuel
    Aren Frontera, Osvaldo
    Brahmer, Julie
    Chow, Laura Q.
    Crino, Lucio
    Butts, Charles
    Coudert, Bruno
    Horn, Leora
    Steins, Martin
    Geese, William J.
    Li, Ang
    Healey, Diane
    Vokes, Everett E.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2017, 13 : 142 - 143
12345